Please ensure Javascript is enabled for purposes of website accessibility

Why Checkpoint Therapeutics Skyrocketed Today

By Eric Volkman - Jun 9, 2021 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One analyst becomes a fervent believer in the company's stock.

What happened

One very big stock market winner on Wednesday was Checkpoint Therapeutics (CKPT 2.50%). Shares of the company zoomed 19% higher after glowing coverage on its stock was initiated by an analyst.

So what

B. Riley Securities prognosticator Justin Walsh is bullish on Checkpoint. Actually, that's understating the case considerably. Walsh is so hot on Checkpoint's prospects, he's initiating his coverage with a buy rating and an $18 per-share price target -- which was nearly seven times Tuesday's closing stock price.

Cancer attacking an organism.

Image source: Getty Images.

Checkpoint is a clinical-stage biotech specializing in immunotherapy solutions for solid tumor cancers. It has one pipeline drug, cosibelimab, that targets certain recurrent or metastatic cancers. Another, CK-101, is intended for the treatment of non-small cell lung cancer. Both are currently in phase 1 clinical trials.

In a research note published on Wednesday, Walsh pointed out that his estimate of the company's revenue and cash flow growth through 2028 shows that the stock could increase by around 600%.

Cosibelimab could have a very bright future; Walsh wrote that comparable therapies "achieved [over] $15 billion in sales in 2020 in the U.S. alone, and we conservatively estimate that cosibelimab could achieve $1.3 billion in peak risk-unadjusted net sales (U.S., European Union, and U.K.)."

Now what

With its tight focus on cancer immunotherapy, Checkpoint operates in a hot area of biotech just now. And with this glowing research note, it's going to be on the radar of many investors, and therefore a high-potential stock certainly worth watching.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Checkpoint Therapeutics, Inc. Stock Quote
Checkpoint Therapeutics, Inc.
$1.23 (2.50%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.